About stoke therapeutics inc - STOK
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
STOK At a Glance
Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford, Massachusetts 01730
| Phone | 1-781-430-8200 | Revenue | 184.42M | |
| Industry | Biotechnology | Net Income | -6,885,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 404.5% | |
| Fiscal Year-end | 12 / 2026 | Employees | 170 | |
| View SEC Filings |
STOK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.192 |
| Price to Book Ratio | 5.306 |
| Price to Cash Flow Ratio | 41.23 |
| Enterprise Value to EBITDA | -97.404 |
| Enterprise Value to Sales | 8.668 |
| Total Debt to Enterprise Value | 0.003 |
STOK Efficiency
| Revenue/Employee | 1,084,823.529 |
| Income Per Employee | -40,500.00 |
| Receivables Turnover | 23.33 |
| Total Asset Turnover | 0.535 |
STOK Liquidity
| Current Ratio | 5.282 |
| Quick Ratio | 5.282 |
| Cash Ratio | 4.927 |
STOK Profitability
| Gross Margin | 97.735 |
| Operating Margin | -11.165 |
| Pretax Margin | -3.733 |
| Net Margin | -3.733 |
| Return on Assets | -1.996 |
| Return on Equity | -2.368 |
| Return on Total Capital | -1.931 |
| Return on Invested Capital | -2.354 |
STOK Capital Structure
| Total Debt to Total Equity | 1.177 |
| Total Debt to Total Capital | 1.163 |
| Total Debt to Total Assets | 0.991 |
| Long-Term Debt to Equity | 0.324 |
| Long-Term Debt to Total Capital | 0.32 |